Ciclesonide for the treatment of airway hyperresponsiveness

Study identifier:BY9010/CH-101

ClinicalTrials.gov identifier:NCT00826969

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Ciclesonide for the treatment of airway hyperresponsiveness. The Mannitol-Asthma-Ciclesonide Study (MACS). A double-blind, randomized, parallel group study.

Medical condition

asthma

Phase

Phase 4

Healthy volunteers

No

Study drug

Ciclesonide, Placebo

Sex

All

Actual Enrollment

64

Study type

Interventional

Age

18 Years - 70 Years

Date

Study Start Date: 01 Sept 2008
Primary Completion Date: 01 Jul 2010
Study Completion Date: 01 Oct 2011

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Oct 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria